Compare NUVL & VMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUVL | VMI |
|---|---|---|
| Founded | 2017 | 1946 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Metal Fabrications |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0B | 8.1B |
| IPO Year | 2021 | N/A |
| Metric | NUVL | VMI |
|---|---|---|
| Price | $100.82 | $475.33 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 4 |
| Target Price | $135.00 | ★ $462.33 |
| AVG Volume (30 Days) | ★ 497.6K | 115.3K |
| Earning Date | 02-27-2026 | 02-17-2026 |
| Dividend Yield | N/A | ★ 0.58% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 11.66 |
| Revenue | N/A | ★ $4,103,136,000.00 |
| Revenue This Year | N/A | $1.86 |
| Revenue Next Year | N/A | $4.12 |
| P/E Ratio | ★ N/A | $40.09 |
| Revenue Growth | N/A | ★ 1.23 |
| 52 Week Low | $55.54 | $250.07 |
| 52 Week High | $113.02 | $487.58 |
| Indicator | NUVL | VMI |
|---|---|---|
| Relative Strength Index (RSI) | 49.64 | 67.46 |
| Support Level | $98.65 | $463.43 |
| Resistance Level | $106.57 | $487.58 |
| Average True Range (ATR) | 4.46 | 12.28 |
| MACD | -0.29 | 0.95 |
| Stochastic Oscillator | 47.36 | 72.02 |
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
Valmont Industries Inc, along with its subsidiaries, operates as a manufacturer of products and services for infrastructure and agriculture markets. Its reportable segments are Infrastructure and Agriculture. The company generates maximum revenue from the Infrastructure segment, which includes the manufacturing and distribution of products and solutions to serve the infrastructure markets of utility, solar, lighting and transportation, and telecommunications, along with coatings services to protect metal products. The Agriculture segment provides irrigation equipment components, including aftermarket parts and tubular products, and technology solutions for precision agriculture. Geographically, it derives key revenue from the United States, followed by Australia, Brazil, and other regions.